Future studies assessing efficacy of treatment with AZD7325 or other GABRA2-selective PAMs on spontaneous seizures and survival would provide further support for targeting α2-containing GABAA receptors for the treatment of Dravet syndrome and, potentially, other DEEs that share reduced GABAergic signaling as a common pathogenic mechanism. Here, GABRA2 is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.